Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu

Podcasts > Archived Podcasts > Industry Focus

This show is no longer producing new episodes. Check out our other shows.

Industry Focus

Industry Focus Logo

Healthcare: Is Zolgensma's $2.1 Million Price Tag Ridiculous?

May 29, 2019 (23:14)

Here's why paying $2 million for Novartis' revolutionary gene therapy for SMA may not be as crazy as it sounds. 
Also, why shares slumped after BioMarin reported its gene therapy may virtually eliminate bleeding in hemophilia A patients.

Check out more of our content here:

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.